logo-loader
viewArix Bioscience PLC

Arix Bioscience’s portfolio company Autolus announces positive safety data for AUTO3 ahead of inaugural R&D day

Updated data from the ongoing AMELIA Phase I/II study showed that all six patients treated at the highest dose achieved minimal residual disease negative complete responses

blood cancer
A patient who tests MRD negative has less than one cancer cell per million bone marrow cells

Arix Bioscience PLC’s (LON:ARIX) portfolio company, Autolus Therapeutics, has announced positive updated safety and efficacy data for its AUTO3 leukaemia drug ahead of its inaugural R&D day in New York.

Updated data from the ongoing AMELIA Phase I/II study showed that all six patients treated at the highest dose achieved minimal residual disease (MRD) negative complete responses (CR).

READ: Arix invests US$15mln in sickle cell treatment developer

A patient who tests MRD negative has less than one cancer cell per million bone marrow cells, meaning the disease is all but gone.

Ongoing MRD negative CR remissions were noted in four of the six patients, with duration of up to 10 months as of February 2019, the date of latest data follow-up.

Nasdaq-listed Autolus added that AUTO3 continues to be generally well tolerated with none of the patients needing critical care for cytokine release syndrome – a condition that occurs with some forms of immunotherapy.

The Phase II portion of the study remains on track to begin in the second half of this year.

R&D day later today

Autolus made the announcement ahead of its inaugural R&D day in New York which is due to get underway later today.

Chairman and chief executive Christian Itin will be one of those giving a presentation, as will several other execs.

“We are pleased to be hosting our inaugural R&D day, providing a unique opportunity to present an in-depth overview of our differentiated technology, multiple programs, market opportunities and the significant pipeline progress we have achieved, to date,” said Autolus boss Itin.

“We expect to report data on all of our active clinical programs at key medical conferences during 2019. Additionally, over the coming months, we expect to move two programs into registrational trials and to progress our next generation programs toward the clinic.”

Shares in Arix, which has results out on Thursday, edged 1% higher to 145.5p in late-morning trading on Tuesday.

Quick facts: Arix Bioscience PLC

Price: 113.5 GBX

LSE:ARIX
Market: LSE
Market Cap: £153.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read